1 C-MET / HGF Inhibitors Market Overview 1.1 Product Overview and Scope of C-MET / HGF Inhibitors 1.2 C-MET / HGF Inhibitors Segment by Type 1.2.1 Global C-MET / HGF Inhibitors Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 C-Met Biologic Inhibitors 1.2.3 Small Molecule C-Met Inhibitors 1.2.4 HGF Antagonist Antibodies 1.2.5 C-Met Antagonist Antibodies(MetMAb) 1.2.6 HGF Kringle Variant Antagonists 1.3 C-MET / HGF Inhibitors Segment by Application 1.3.1 Global C-MET / HGF Inhibitors Sales Comparison by Application: (2021-2027) 1.3.2 Hospital Pharmacies 1.3.3 Retail Pharmacies 1.3.4 Drug Stores 1.3.5 Online Sales 1.4 Global C-MET / HGF Inhibitors Market Size Estimates and Forecasts 1.4.1 Global C-MET / HGF Inhibitors Revenue 2016-2027 1.4.2 Global C-MET / HGF Inhibitors Sales 2016-2027 1.4.3 C-MET / HGF Inhibitors Market Size by Region: 2016 Versus 2021 Versus 2027 2 C-MET / HGF Inhibitors Market Competition by Manufacturers 2.1 Global C-MET / HGF Inhibitors Sales Market Share by Manufacturers (2016-2021) 2.2 Global C-MET / HGF Inhibitors Revenue Market Share by Manufacturers (2016-2021) 2.3 Global C-MET / HGF Inhibitors Average Price by Manufacturers (2016-2021) 2.4 Manufacturers C-MET / HGF Inhibitors Manufacturing Sites, Area Served, Product Type 2.5 C-MET / HGF Inhibitors Market Competitive Situation and Trends 2.5.1 C-MET / HGF Inhibitors Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest C-MET / HGF Inhibitors Players Market Share by Revenue 2.5.3 Global C-MET / HGF Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 C-MET / HGF Inhibitors Retrospective Market Scenario by Region 3.1 Global C-MET / HGF Inhibitors Retrospective Market Scenario in Sales by Region: 2016-2021 3.2 Global C-MET / HGF Inhibitors Retrospective Market Scenario in Revenue by Region: 2016-2021 3.3 North America C-MET / HGF Inhibitors Market Facts & Figures by Country 3.3.1 North America C-MET / HGF Inhibitors Sales by Country 3.3.2 North America C-MET / HGF Inhibitors Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe C-MET / HGF Inhibitors Market Facts & Figures by Country 3.4.1 Europe C-MET / HGF Inhibitors Sales by Country 3.4.2 Europe C-MET / HGF Inhibitors Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific C-MET / HGF Inhibitors Market Facts & Figures by Region 3.5.1 Asia Pacific C-MET / HGF Inhibitors Sales by Region 3.5.2 Asia Pacific C-MET / HGF Inhibitors Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America C-MET / HGF Inhibitors Market Facts & Figures by Country 3.6.1 Latin America C-MET / HGF Inhibitors Sales by Country 3.6.2 Latin America C-MET / HGF Inhibitors Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa C-MET / HGF Inhibitors Market Facts & Figures by Country 3.7.1 Middle East and Africa C-MET / HGF Inhibitors Sales by Country 3.7.2 Middle East and Africa C-MET / HGF Inhibitors Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global C-MET / HGF Inhibitors Historic Market Analysis by Type 4.1 Global C-MET / HGF Inhibitors Sales Market Share by Type (2016-2021) 4.2 Global C-MET / HGF Inhibitors Revenue Market Share by Type (2016-2021) 4.3 Global C-MET / HGF Inhibitors Price by Type (2016-2021) 5 Global C-MET / HGF Inhibitors Historic Market Analysis by Application 5.1 Global C-MET / HGF Inhibitors Sales Market Share by Application (2016-2021) 5.2 Global C-MET / HGF Inhibitors Revenue Market Share by Application (2016-2021) 5.3 Global C-MET / HGF Inhibitors Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Abxign 6.1.1 Abxign Corporation Information 6.1.2 Abxign Description and Business Overview 6.1.3 Abxign C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Abxign C-MET / HGF Inhibitors Product Portfolio 6.1.5 Abxign Recent Developments/Updates 6.2 Abbott Laboratories 6.2.1 Abbott Laboratories Corporation Information 6.2.2 Abbott Laboratories Description and Business Overview 6.2.3 Abbott Laboratories C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.2.4 Abbott Laboratories C-MET / HGF Inhibitors Product Portfolio 6.2.5 Abbott Laboratories Recent Developments/Updates 6.3 Amgen 6.3.1 Amgen Corporation Information 6.3.2 Amgen Description and Business Overview 6.3.3 Amgen C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Amgen C-MET / HGF Inhibitors Product Portfolio 6.3.5 Amgen Recent Developments/Updates 6.4 ArQule 6.4.1 ArQule Corporation Information 6.4.2 ArQule Description and Business Overview 6.4.3 ArQule C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.4.4 ArQule C-MET / HGF Inhibitors Product Portfolio 6.4.5 ArQule Recent Developments/Updates 6.5 Astex Therapeutics 6.5.1 Astex Therapeutics Corporation Information 6.5.2 Astex Therapeutics Description and Business Overview 6.5.3 Astex Therapeutics C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.5.4 Astex Therapeutics C-MET / HGF Inhibitors Product Portfolio 6.5.5 Astex Therapeutics Recent Developments/Updates 6.6 AVEO Pharmaceuticals 6.6.1 AVEO Pharmaceuticals Corporation Information 6.6.2 AVEO Pharmaceuticals Description and Business Overview 6.6.3 AVEO Pharmaceuticals C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.6.4 AVEO Pharmaceuticals C-MET / HGF Inhibitors Product Portfolio 6.6.5 AVEO Pharmaceuticals Recent Developments/Updates 6.7 Bristol-Myers Squibb(BMS) 6.6.1 Bristol-Myers Squibb(BMS) Corporation Information 6.6.2 Bristol-Myers Squibb(BMS) Description and Business Overview 6.6.3 Bristol-Myers Squibb(BMS) C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Bristol-Myers Squibb(BMS) C-MET / HGF Inhibitors Product Portfolio 6.7.5 Bristol-Myers Squibb(BMS) Recent Developments/Updates 6.8 Chroma Therapeutics 6.8.1 Chroma Therapeutics Corporation Information 6.8.2 Chroma Therapeutics Description and Business Overview 6.8.3 Chroma Therapeutics C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.8.4 Chroma Therapeutics C-MET / HGF Inhibitors Product Portfolio 6.8.5 Chroma Therapeutics Recent Developments/Updates 6.9 Daiichi Sankyo 6.9.1 Daiichi Sankyo Corporation Information 6.9.2 Daiichi Sankyo Description and Business Overview 6.9.3 Daiichi Sankyo C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.9.4 Daiichi Sankyo C-MET / HGF Inhibitors Product Portfolio 6.9.5 Daiichi Sankyo Recent Developments/Updates 6.10 Deciphera Pharmaceuticals 6.10.1 Deciphera Pharmaceuticals Corporation Information 6.10.2 Deciphera Pharmaceuticals Description and Business Overview 6.10.3 Deciphera Pharmaceuticals C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.10.4 Deciphera Pharmaceuticals C-MET / HGF Inhibitors Product Portfolio 6.10.5 Deciphera Pharmaceuticals Recent Developments/Updates 6.11 Eisai 6.11.1 Eisai Corporation Information 6.11.2 Eisai C-MET / HGF Inhibitors Description and Business Overview 6.11.3 Eisai C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.11.4 Eisai C-MET / HGF Inhibitors Product Portfolio 6.11.5 Eisai Recent Developments/Updates 6.12 Eli Lilly 6.12.1 Eli Lilly Corporation Information 6.12.2 Eli Lilly C-MET / HGF Inhibitors Description and Business Overview 6.12.3 Eli Lilly C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.12.4 Eli Lilly C-MET / HGF Inhibitors Product Portfolio 6.12.5 Eli Lilly Recent Developments/Updates 6.13 Exelixis 6.13.1 Exelixis Corporation Information 6.13.2 Exelixis C-MET / HGF Inhibitors Description and Business Overview 6.13.3 Exelixis C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.13.4 Exelixis C-MET / HGF Inhibitors Product Portfolio 6.13.5 Exelixis Recent Developments/Updates 6.14 Genmab 6.14.1 Genmab Corporation Information 6.14.2 Genmab C-MET / HGF Inhibitors Description and Business Overview 6.14.3 Genmab C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.14.4 Genmab C-MET / HGF Inhibitors Product Portfolio 6.14.5 Genmab Recent Developments/Updates 6.15 Galaxy Biotech 6.15.1 Galaxy Biotech Corporation Information 6.15.2 Galaxy Biotech C-MET / HGF Inhibitors Description and Business Overview 6.15.3 Galaxy Biotech C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.15.4 Galaxy Biotech C-MET / HGF Inhibitors Product Portfolio 6.15.5 Galaxy Biotech Recent Developments/Updates 6.16 GlaxoSmithKline(GSK) 6.16.1 GlaxoSmithKline(GSK) Corporation Information 6.16.2 GlaxoSmithKline(GSK) C-MET / HGF Inhibitors Description and Business Overview 6.16.3 GlaxoSmithKline(GSK) C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.16.4 GlaxoSmithKline(GSK) C-MET / HGF Inhibitors Product Portfolio 6.16.5 GlaxoSmithKline(GSK) Recent Developments/Updates 6.17 Hutchison MediPharma 6.17.1 Hutchison MediPharma Corporation Information 6.17.2 Hutchison MediPharma C-MET / HGF Inhibitors Description and Business Overview 6.17.3 Hutchison MediPharma C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.17.4 Hutchison MediPharma C-MET / HGF Inhibitors Product Portfolio 6.17.5 Hutchison MediPharma Recent Developments/Updates 6.18 Johnson & Johnson 6.18.1 Johnson & Johnson Corporation Information 6.18.2 Johnson & Johnson C-MET / HGF Inhibitors Description and Business Overview 6.18.3 Johnson & Johnson C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.18.4 Johnson & Johnson C-MET / HGF Inhibitors Product Portfolio 6.18.5 Johnson & Johnson Recent Developments/Updates 6.19 Kringle Pharmaceuticals 6.19.1 Kringle Pharmaceuticals Corporation Information 6.19.2 Kringle Pharmaceuticals C-MET / HGF Inhibitors Description and Business Overview 6.19.3 Kringle Pharmaceuticals C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.19.4 Kringle Pharmaceuticals C-MET / HGF Inhibitors Product Portfolio 6.19.5 Kringle Pharmaceuticals Recent Developments/Updates 6.20 Merck 6.20.1 Merck Corporation Information 6.20.2 Merck C-MET / HGF Inhibitors Description and Business Overview 6.20.3 Merck C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.20.4 Merck C-MET / HGF Inhibitors Product Portfolio 6.20.5 Merck Recent Developments/Updates 6.21 Methylgene 6.21.1 Methylgene Corporation Information 6.21.2 Methylgene C-MET / HGF Inhibitors Description and Business Overview 6.21.3 Methylgene C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.21.4 Methylgene C-MET / HGF Inhibitors Product Portfolio 6.21.5 Methylgene Recent Developments/Updates 6.22 Novartis 6.22.1 Novartis Corporation Information 6.22.2 Novartis C-MET / HGF Inhibitors Description and Business Overview 6.22.3 Novartis C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.22.4 Novartis C-MET / HGF Inhibitors Product Portfolio 6.22.5 Novartis Recent Developments/Updates 6.23 Pfizer 6.23.1 Pfizer Corporation Information 6.23.2 Pfizer C-MET / HGF Inhibitors Description and Business Overview 6.23.3 Pfizer C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.23.4 Pfizer C-MET / HGF Inhibitors Product Portfolio 6.23.5 Pfizer Recent Developments/Updates 6.24 ProMetic BioTherapeutics 6.24.1 ProMetic BioTherapeutics Corporation Information 6.24.2 ProMetic BioTherapeutics C-MET / HGF Inhibitors Description and Business Overview 6.24.3 ProMetic BioTherapeutics C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.24.4 ProMetic BioTherapeutics C-MET / HGF Inhibitors Product Portfolio 6.24.5 ProMetic BioTherapeutics Recent Developments/Updates 6.25 Takeda Pharmaceutical 6.25.1 Takeda Pharmaceutical Corporation Information 6.25.2 Takeda Pharmaceutical C-MET / HGF Inhibitors Description and Business Overview 6.25.3 Takeda Pharmaceutical C-MET / HGF Inhibitors Sales, Revenue and Gross Margin (2016-2021) 6.25.4 Takeda Pharmaceutical C-MET / HGF Inhibitors Product Portfolio 6.25.5 Takeda Pharmaceutical Recent Developments/Updates 7 C-MET / HGF Inhibitors Manufacturing Cost Analysis 7.1 C-MET / HGF Inhibitors Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of C-MET / HGF Inhibitors 7.4 C-MET / HGF Inhibitors Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 C-MET / HGF Inhibitors Distributors List 8.3 C-MET / HGF Inhibitors Customers 9 C-MET / HGF Inhibitors Market Dynamics 9.1 C-MET / HGF Inhibitors Industry Trends 9.2 C-MET / HGF Inhibitors Growth Drivers 9.3 C-MET / HGF Inhibitors Market Challenges 9.4 C-MET / HGF Inhibitors Market Restraints 10 Global Market Forecast 10.1 C-MET / HGF Inhibitors Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of C-MET / HGF Inhibitors by Type (2022-2027) 10.1.2 Global Forecasted Revenue of C-MET / HGF Inhibitors by Type (2022-2027) 10.2 C-MET / HGF Inhibitors Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of C-MET / HGF Inhibitors by Application (2022-2027) 10.2.2 Global Forecasted Revenue of C-MET / HGF Inhibitors by Application (2022-2027) 10.3 C-MET / HGF Inhibitors Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of C-MET / HGF Inhibitors by Region (2022-2027) 10.3.2 Global Forecasted Revenue of C-MET / HGF Inhibitors by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global C-MET / HGF Inhibitors Sales (K MT) Growth Rate Comparison by Type (2021-2027) Table 2. Global C-MET / HGF Inhibitors Sales (K MT) Comparison by Application (2021-2027) Table 3. Global C-MET / HGF Inhibitors Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers C-MET / HGF Inhibitors Covered in This Study Table 5. Global C-MET / HGF Inhibitors Sales (K MT) of Key Manufacturers (2016-2021) Table 6. Global C-MET / HGF Inhibitors Sales Market Share by Manufacturers (2016-2021) Table 7. Global C-MET / HGF Inhibitors Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global C-MET / HGF Inhibitors Revenue Share by Manufacturers (2016-2021) Table 9. Global Market C-MET / HGF Inhibitors Average Price (USD/MT) of Key Manufacturers (2016-2021) Table 10. Manufacturers C-MET / HGF Inhibitors Manufacturing Sites and Area Served Table 11. Manufacturers C-MET / HGF Inhibitors Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global C-MET / HGF Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in C-MET / HGF Inhibitors as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global C-MET / HGF Inhibitors Sales by Region (2016-2021) & (K MT) Table 16. Global C-MET / HGF Inhibitors Sales Market Share by Region (2016-2021) Table 17. Global C-MET / HGF Inhibitors Revenue by Region (2016-2021) & (US$ Million) Table 18. North America C-MET / HGF Inhibitors Sales by Country (2016-2021) & (K MT) Table 19. North America C-MET / HGF Inhibitors Sales Market Share by Country (2016-2021) Table 20. North America C-MET / HGF Inhibitors Revenue by Country (2016-2021) & (US$ Million) Table 21. North America C-MET / HGF Inhibitors Revenue Market Share by Country (2016-2021) Table 22. Europe C-MET / HGF Inhibitors Sales by Country (2016-2021) & (K MT) Table 23. Europe C-MET / HGF Inhibitors Sales Market Share by Country (2016-2021) Table 24. Europe C-MET / HGF Inhibitors Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe C-MET / HGF Inhibitors Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific C-MET / HGF Inhibitors Sales by Region (2016-2021) & (K MT) Table 27. Asia Pacific C-MET / HGF Inhibitors Sales Market Share by Region (2016-2021) Table 28. Asia Pacific C-MET / HGF Inhibitors Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific C-MET / HGF Inhibitors Revenue Market Share by Region (2016-2021) Table 30. Latin America C-MET / HGF Inhibitors Sales by Country (2016-2021) & (K MT) Table 31. Latin America C-MET / HGF Inhibitors Sales Market Share by Country (2016-2021) Table 32. Latin America C-MET / HGF Inhibitors Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America C-MET / HGF Inhibitors Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa C-MET / HGF Inhibitors Sales by Country (2016-2021) & (K MT) Table 35. Middle East and Africa C-MET / HGF Inhibitors Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa C-MET / HGF Inhibitors Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa C-MET / HGF Inhibitors Revenue Market Share by Country (2016-2021) Table 38. Global C-MET / HGF Inhibitors Sales (K MT) by Type (2016-2021) Table 39. Global C-MET / HGF Inhibitors Sales Market Share by Type (2016-2021) Table 40. Global C-MET / HGF Inhibitors Revenue (Million US$) by Type (2016-2021) Table 41. Global C-MET / HGF Inhibitors Revenue Share by Type (2016-2021) Table 42. Global C-MET / HGF Inhibitors Price (USD/MT) by Type (2016-2021) Table 43. Global C-MET / HGF Inhibitors Sales (K MT) by Application (2016-2021) Table 44. Global C-MET / HGF Inhibitors Sales Market Share by Application (2016-2021) Table 45. Global C-MET / HGF Inhibitors Revenue (Million US$) by Application (2016-2021) Table 46. Global C-MET / HGF Inhibitors Revenue Share by Application (2016-2021) Table 47. Global C-MET / HGF Inhibitors Price (USD/MT) by Application (2016-2021) Table 48. Abxign Corporation Information Table 49. Abxign Description and Business Overview Table 50. Abxign C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 51. Abxign C-MET / HGF Inhibitors Product Table 52. Abxign Recent Developments/Updates Table 53. Abbott Laboratories Corporation Information Table 54. Abbott Laboratories Description and Business Overview Table 55. Abbott Laboratories C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 56. Abbott Laboratories C-MET / HGF Inhibitors Product Table 57. Abbott Laboratories Recent Developments/Updates Table 58. Amgen Corporation Information Table 59. Amgen Description and Business Overview Table 60. Amgen C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 61. Amgen C-MET / HGF Inhibitors Product Table 62. Amgen Recent Developments/Updates Table 63. ArQule Corporation Information Table 64. ArQule Description and Business Overview Table 65. ArQule C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 66. ArQule C-MET / HGF Inhibitors Product Table 67. ArQule Recent Developments/Updates Table 68. Astex Therapeutics Corporation Information Table 69. Astex Therapeutics Description and Business Overview Table 70. Astex Therapeutics C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 71. Astex Therapeutics C-MET / HGF Inhibitors Product Table 72. Astex Therapeutics Recent Developments/Updates Table 73. AVEO Pharmaceuticals Corporation Information Table 74. AVEO Pharmaceuticals Description and Business Overview Table 75. AVEO Pharmaceuticals C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 76. AVEO Pharmaceuticals C-MET / HGF Inhibitors Product Table 77. AVEO Pharmaceuticals Recent Developments/Updates Table 78. Bristol-Myers Squibb(BMS) Corporation Information Table 79. Bristol-Myers Squibb(BMS) Description and Business Overview Table 80. Bristol-Myers Squibb(BMS) C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 81. Bristol-Myers Squibb(BMS) C-MET / HGF Inhibitors Product Table 82. Bristol-Myers Squibb(BMS) Recent Developments/Updates Table 83. Chroma Therapeutics Corporation Information Table 84. Chroma Therapeutics Description and Business Overview Table 85. Chroma Therapeutics C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 86. Chroma Therapeutics C-MET / HGF Inhibitors Product Table 87. Chroma Therapeutics Recent Developments/Updates Table 88. Daiichi Sankyo Corporation Information Table 89. Daiichi Sankyo Description and Business Overview Table 90. Daiichi Sankyo C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 91. Daiichi Sankyo C-MET / HGF Inhibitors Product Table 92. Daiichi Sankyo Recent Developments/Updates Table 93. Deciphera Pharmaceuticals Corporation Information Table 94. Deciphera Pharmaceuticals Description and Business Overview Table 95. Deciphera Pharmaceuticals C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 96. Deciphera Pharmaceuticals C-MET / HGF Inhibitors Product Table 97. Deciphera Pharmaceuticals Recent Developments/Updates Table 98. Eisai Corporation Information Table 99. Eisai Description and Business Overview Table 100. Eisai C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 101. Eisai C-MET / HGF Inhibitors Product Table 102. Eisai Recent Developments/Updates Table 103. Eli Lilly Corporation Information Table 104. Eli Lilly Description and Business Overview Table 105. Eli Lilly C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 106. Eli Lilly C-MET / HGF Inhibitors Product Table 107. Eli Lilly Recent Developments/Updates Table 108. Exelixis Corporation Information Table 109. Exelixis Description and Business Overview Table 110. Exelixis C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 111. Exelixis C-MET / HGF Inhibitors Product Table 112. Exelixis Recent Developments/Updates Table 113. Genmab Corporation Information Table 114. Genmab Description and Business Overview Table 115. Genmab C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 116. Genmab C-MET / HGF Inhibitors Product Table 117. Genmab Recent Developments/Updates Table 118. Galaxy Biotech Corporation Information Table 119. Galaxy Biotech Description and Business Overview Table 120. Galaxy Biotech C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 121. Galaxy Biotech C-MET / HGF Inhibitors Product Table 122. Galaxy Biotech Recent Developments/Updates Table 123. GlaxoSmithKline(GSK) Corporation Information Table 124. GlaxoSmithKline(GSK) Description and Business Overview Table 125. GlaxoSmithKline(GSK) C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 126. GlaxoSmithKline(GSK) C-MET / HGF Inhibitors Product Table 127. GlaxoSmithKline(GSK) Recent Developments/Updates Table 128. Hutchison MediPharma Corporation Information Table 129. Hutchison MediPharma Description and Business Overview Table 130. Hutchison MediPharma C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 131. Hutchison MediPharma C-MET / HGF Inhibitors Product Table 132. Hutchison MediPharma Recent Developments/Updates Table 133. Johnson & Johnson Corporation Information Table 134. Johnson & Johnson Description and Business Overview Table 135. Johnson & Johnson C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 136. Johnson & Johnson C-MET / HGF Inhibitors Product Table 137. Johnson & Johnson Recent Developments/Updates Table 138. Kringle Pharmaceuticals Corporation Information Table 139. Kringle Pharmaceuticals Description and Business Overview Table 140. Kringle Pharmaceuticals C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 141. Kringle Pharmaceuticals C-MET / HGF Inhibitors Product Table 142. Kringle Pharmaceuticals Recent Developments/Updates Table 143. Merck Corporation Information Table 144. Merck Description and Business Overview Table 145. Merck C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 146. Merck C-MET / HGF Inhibitors Product Table 147. Merck Recent Developments/Updates Table 148. Methylgene Corporation Information Table 149. Methylgene Description and Business Overview Table 150. Methylgene C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 151. Methylgene C-MET / HGF Inhibitors Product Table 152. Methylgene Recent Developments/Updates Table 153. Novartis Corporation Information Table 154. Novartis Description and Business Overview Table 155. Novartis C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 156. Novartis C-MET / HGF Inhibitors Product Table 157. Novartis Recent Developments/Updates Table 158. Pfizer Corporation Information Table 159. Pfizer Description and Business Overview Table 160. Pfizer C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 161. Pfizer C-MET / HGF Inhibitors Product Table 162. Pfizer Recent Developments/Updates Table 163. ProMetic BioTherapeutics Corporation Information Table 164. ProMetic BioTherapeutics Description and Business Overview Table 165. ProMetic BioTherapeutics C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 166. ProMetic BioTherapeutics C-MET / HGF Inhibitors Product Table 167. ProMetic BioTherapeutics Recent Developments/Updates Table 168. Takeda Pharmaceutical Corporation Information Table 169. Takeda Pharmaceutical Description and Business Overview Table 170. Takeda Pharmaceutical C-MET / HGF Inhibitors Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021) Table 171. Takeda Pharmaceutical C-MET / HGF Inhibitors Product Table 172. Takeda Pharmaceutical Recent Developments/Updates Table 173. Production Base and Market Concentration Rate of Raw Material Table 174. Key Suppliers of Raw Materials Table 175. C-MET / HGF Inhibitors Distributors List Table 176. C-MET / HGF Inhibitors Customers List Table 177. C-MET / HGF Inhibitors Market Trends Table 178. C-MET / HGF Inhibitors Growth Drivers Table 179. C-MET / HGF Inhibitors Market Challenges Table 180. C-MET / HGF Inhibitors Market Restraints Table 181. Global C-MET / HGF Inhibitors Sales Forecast by Type (2022-2027) & (K MT) Table 182. Global C-MET / HGF Inhibitors Sales Market Share Forecast by Type (2022-2027) Table 183. Global C-MET / HGF Inhibitors Revenue Forecast by Type (2022-2027) & (US$ Million) Table 184. Global C-MET / HGF Inhibitors Revenue Market Share Forecast by Type (2022-2027) Table 185. Global C-MET / HGF Inhibitors Sales Forecast by Application (2022-2027) & (K MT) Table 186. Global C-MET / HGF Inhibitors Sales Market Share Forecast by Application (2022-2027) Table 187. Global C-MET / HGF Inhibitors Revenue Forecast by Application (2022-2027) & (US$ Million) Table 188. Global C-MET / HGF Inhibitors Revenue Market Share Forecast by Application (2022-2027) Table 189. Global C-MET / HGF Inhibitors Sales Forecast by Region (2022-2027) & (K MT) Table 190. Global C-MET / HGF Inhibitors Sales Market Share Forecast by Region (2022-2027) Table 191. Global C-MET / HGF Inhibitors Revenue Forecast by Region (2022-2027) & (US$ Million) Table 192. Global C-MET / HGF Inhibitors Revenue Market Share Forecast by Region (2022-2027) Table 193. Research Programs/Design for This Report Table 194. Key Data Information from Secondary Sources Table 195. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of C-MET / HGF Inhibitors Figure 2. Global C-MET / HGF Inhibitors Market Share by Type in 2020 & 2027 Figure 3. C-Met Biologic Inhibitors Product Picture Figure 4. Small Molecule C-Met Inhibitors Product Picture Figure 5. HGF Antagonist Antibodies Product Picture Figure 6. C-Met Antagonist Antibodies(MetMAb) Product Picture Figure 7. HGF Kringle Variant Antagonists Product Picture Figure 8. Global C-MET / HGF Inhibitors Market Share by Application in 2020 & 2027 Figure 9. Hospital Pharmacies Figure 10. Retail Pharmacies Figure 11. Drug Stores Figure 12. Online Sales Figure 13. Global C-MET / HGF Inhibitors Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 14. Global C-MET / HGF Inhibitors Market Size 2016-2027 (US$ Million) Figure 15. Global C-MET / HGF Inhibitors Sales 2016-2027 (K MT) Figure 16. Global C-MET / HGF Inhibitors Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 17. C-MET / HGF Inhibitors Sales Share by Manufacturers in 2020 Figure 18. Global C-MET / HGF Inhibitors Revenue Share by Manufacturers in 2020 Figure 19. The Global 5 and 10 Largest C-MET / HGF Inhibitors Players: Market Share by Revenue in 2020 Figure 20. C-MET / HGF Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 21. Global C-MET / HGF Inhibitors Sales Market Share by Region (2016-2021) Figure 22. Global C-MET / HGF Inhibitors Sales Market Share by Region in 2020 Figure 23. Global C-MET / HGF Inhibitors Revenue Market Share by Region (2016-2021) Figure 24. Global C-MET / HGF Inhibitors Revenue Market Share by Region in 2020 Figure 25. U.S. C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. Canada C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. Germany C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. France C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. U.K. C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. Italy C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. Russia C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. China C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. Japan C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. South Korea C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. India C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Australia C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Taiwan C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Indonesia C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Thailand C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Malaysia C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Philippines C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Vietnam C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Mexico C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Brazil C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Argentina C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. Turkey C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 47. Saudi Arabia C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 48. U.A.E C-MET / HGF Inhibitors Revenue Growth Rate (2016-2021) (US$ Million) Figure 49. Sales Market Share of C-MET / HGF Inhibitors by Type (2016-2021) Figure 50. Sales Market Share of C-MET / HGF Inhibitors by Application (2016-2021) Figure 51. Sales Market Share of C-MET / HGF Inhibitors by Application in 2020 Figure 52. Revenue Share of C-MET / HGF Inhibitors by Application (2016-2021) Figure 53. Revenue Share of C-MET / HGF Inhibitors by Application in 2020 Figure 54. Manufacturing Cost Structure of C-MET / HGF Inhibitors Figure 55. Manufacturing Process Analysis of C-MET / HGF Inhibitors Figure 56. C-MET / HGF Inhibitors Industrial Chain Analysis Figure 57. Channels of Distribution Figure 58. Distributors Profiles Figure 59. Bottom-up and Top-down Approaches for This Report Figure 60. Data Triangulation Figure 61. Key Executives Interviewed

Abxign Abbott Laboratories Amgen ArQule Astex Therapeutics AVEO Pharmaceuticals Bristol-Myers Squibb(BMS) Chroma Therapeutics Daiichi Sankyo Deciphera Pharmaceuticals Eisai Eli Lilly Exelixis Genmab Galaxy Biotech GlaxoSmithKline(GSK) Hutchison MediPharma Johnson & Johnson Kringle Pharmaceuticals Merck Methylgene Novartis Pfizer ProMetic BioTherapeutics Takeda Pharmaceutical